Takeda Pharms Usa Company Profile

✉ Email this page to a colleague

What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?

TAKEDA PHARMS USA has forty approved drugs.

There are one hundred and six US patents protecting TAKEDA PHARMS USA drugs.

There are one thousand four hundred and twenty-seven patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in nineteen countries.

Summary for Takeda Pharms Usa

International Patents:	1427
US Patents:	106
Tradenames:	43
Ingredients:	33
NDAs:	40

Drugs and US Patents for Takeda Pharms Usa

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-006	Mar 27, 2012		DISCN	No	No	7,528,104	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Takeda Pharms Usa	ROZEREM	ramelteon	TABLET;ORAL	021782-001	Jul 22, 2005	AB	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	9,175,017	⤷ Try a Trial				⤷ Try a Trial
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	7,442,830	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-001	Dec 14, 2012		RX	Yes	No	11,192,895	⤷ Try a Trial				⤷ Try a Trial
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-002	Mar 27, 2012		DISCN	No	No	7,528,104	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-002	Sep 30, 2013		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Takeda Pharms Usa

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-001	Jan 25, 2013	7,459,428	⤷ Try a Trial
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016	6,939,971*PED	⤷ Try a Trial
Takeda Pharms Usa	MYDAYIS	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	022063-004	Jun 20, 2017	6,913,768	⤷ Try a Trial
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016	6,462,058*PED	⤷ Try a Trial
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	6,866,866	⤷ Try a Trial
Takeda Pharms Usa	ADDERALL XR 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-002	Oct 11, 2001	6,322,819*PED	⤷ Try a Trial
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,150,383	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Chewable Tablet	500 mg, 750 mg and 1000 mg	➤ Subscribe	2008-10-27
➤ Subscribe	Delayed-release Tablets	1.2 g	➤ Subscribe	2009-12-16
➤ Subscribe	Extended-release Tablets	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2009-12-29
➤ Subscribe	Tablets	0.6 mg	➤ Subscribe	2011-12-23
➤ Subscribe	Delayed-release Orally Disinte	15 mg and 30 mg	➤ Subscribe	2006-12-27
➤ Subscribe	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Delayed-release Capsule	30 mg	➤ Subscribe	2010-11-30
➤ Subscribe	Tablets	8 mg	➤ Subscribe	2009-07-22
➤ Subscribe	Extended-release Capsules	37.5 mg and50 mg	➤ Subscribe	2017-08-03
➤ Subscribe	Tablets	40 mg and 80 mg	➤ Subscribe	2013-02-13
➤ Subscribe	Capsules	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg	➤ Subscribe	2011-02-23
➤ Subscribe	Injection	10 mg/mL	➤ Subscribe	2015-08-25
➤ Subscribe	Oral Powder	750 mg and 1000 mg	➤ Subscribe	2015-11-25
➤ Subscribe	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg	➤ Subscribe	2011-09-23
➤ Subscribe	Tablets	15 mg/500 mg and 15 mg/850 mg	➤ Subscribe	2008-03-06
➤ Subscribe	Delayed-release Pellets/Capsul	15 mg and 30 mg	➤ Subscribe	2005-12-05
➤ Subscribe	Tablets	30 mg/2 mg and 30 mg/4 mg	➤ Subscribe	2009-12-22
➤ Subscribe	Capsule	60 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Tablets	6.25 mg, 12.5 mg and 25 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Extended-release Capsules	100 mg and 200 mg	➤ Subscribe	2006-02-02
➤ Subscribe	Tablets	5 mg, 10 mg, 15 mgand 20 mg	➤ Subscribe	2017-10-02
➤ Subscribe	Extended-release Capsules	12.5 mg and 25 mg	➤ Subscribe	2017-08-07
➤ Subscribe	For Injection	3.5 mg/vial	➤ Subscribe	2008-11-20

International Patents for Takeda Pharms Usa Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Portugal	3354276	⤷ Try a Trial
Germany	202004021169	⤷ Try a Trial
Peru	20061389	⤷ Try a Trial
New Zealand	545775	⤷ Try a Trial
South Korea	20050070039	⤷ Try a Trial
Australia	2011202162	⤷ Try a Trial
Finland	2044043	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Takeda Pharms Usa Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	132013902118390	Italy	⤷ Try a Trial	PRODUCT NAME: LINAGLIPTIN + METFORMINA CLORIDRATO(JENTADUETO); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/780/001 A EU/1/12/780/027, 20120720
1436271	1490023-7	Sweden	⤷ Try a Trial	PRODUCT NAME: VORTIOXETINE ELLER ETT FARMACEUTISKT GODTAGBART SYRAADDITIONSSALT DAERAV; REG. NO/DATE: EU/1/13/891 20131218
1586571	CA 2014 00011	Denmark	⤷ Try a Trial	PRODUCT NAME: ALOGLIPTIN; REG. NO/DATE: EU/1/13/844/001-027 20130919
1973545	2013C/073	Belgium	⤷ Try a Trial	PRODUCT NAME: PONATINIB; AUTHORISATION NUMBER AND DATE: EU/1/13/839/001 20130703
1973545	C01973545/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: SWISSMEDIC 63097 12.02.2014
1436271	C20140012 00108	Estonia	⤷ Try a Trial	PRODUCT NAME: VORTIOKSETIIN;REG NO/DATE: K(2013)9715 LOPLIK 20.12.2013
1436271	132014902248131	Italy	⤷ Try a Trial	PRODUCT NAME: VORTIOXETINA O UN SUO SALE DI ADDIZIONE CON UN ACIDO FARMACEUTICAMENTE ACCETTABILE(BRINTELLIX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/891/001-2-3-4-5-6-7, 20131218
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for Takeda Pharms Usa

Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing